Company Description
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.
It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation.
The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.
Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | David-Alexandre Gros |
Contact Details
Address: 19900 MacArthur Boulevard, Suite 550 Irvine, California 92612 United States | |
| Phone | (949) 238-8090 |
| Website | eledon.com |
Stock Details
| Ticker Symbol | ELDN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001404281 |
| CUSIP Number | 28617K101 |
| ISIN Number | US28617K1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David-Alexandre C. Gros M.D., Ph.D. | Chief Executive Officer and Non Independent Director |
| Dr. Steven N. Perrin Ph.D. | President, Chief Scientific Officer and Non Independent Director |
| Paul Sean Little | Chief Financial Officer |
| John Herberger | Vice President of Technical Operations |
| Bryan E. Smith J.D. | General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. David Hovland Ph.D. | Chief Regulatory Officer |
| Dr. Eliezer Katz F.A.C.S., FACS, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2024 | 424B5 | Filing |
| Oct 30, 2024 | 424B5 | Filing |
| Oct 30, 2024 | 8-K | Current Report |